S. Fanti

Publications842
h-index68
Citations17,180
Highly Influential Citations549
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Castellucci
  • 293 Publications, 6,736 Citations
  • C. Nanni
  • 240 Publications, 6,875 Citations
  • A. Briganti
  • 1,920 Publications, 27,200 Citations
  • D. Rubello
  • 802 Publications, 14,654 Citations
  • Publications
  • Influence
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
We prospectively analyzed the prognostic relevance of positron emission tomography-computed tomography (PET/CT) at diagnosis, after thalidomide-dexamethasone (TD) induction therapy and double… Expand
  • 337
  • 26
  • PDF
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
BACKGROUND In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence… Expand
  • 316
  • 18
  • PDF
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
The aim of these guidelines is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin (SST) receptor PET/CT imaging using… Expand
  • 279
  • 18
  • PDF
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA
Purpose & MethodsNeuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic… Expand
  • 101
  • 16
68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
PurposeTo assess the association between PSA levels, PSA kinetics and other factors and a pathological 68Ga-PSMA PET/CT scan in patients with recurrent prostate cancer (rPCa) with biochemical relapse… Expand
  • 207
  • 12
Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
UNLABELLED This study evaluated the potential usefulness of (11)C-choline PET/CT for detection and localization of tumors within the prostate. We used the results of step-section histopathologic… Expand
  • 241
  • 10
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in…
BACKGROUND AND OBJECTIVES Bone lesions in multiple myeloma (MM) have been traditionally detected by whole body X-ray (WBXR) survey although magnetic resonance imaging (MRI) has become the gold… Expand
  • 232
  • 10
Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
PurposeTo retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the… Expand
  • 95
  • 10
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
Several authors reported the superiority of 68Ga-DOTANOC PET/CT to conventional imaging (CI) for the assessment of neuroendocrine tumors (NET). However, the detection of a higher number of lesions is… Expand
  • 209
  • 9
  • PDF
New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
CONTEXT Radiolabelled choline positron emission tomography has changed the management of prostate cancer patients. However, new emerging radiopharmaceutical agents, like radiolabelled prostate… Expand
  • 158
  • 9